English: No, I don't accept the Member's point at all; I think it's hugely important that we are following not just the professional advice but the advice on the safety and effectiveness of the vaccine. And it's important, again, to note that we're talking about this one vaccine, the Pfizer candidate vaccine that's been approved for supply today, which needs to be stored at -70 degrees centigrade. Then, to take that out, as you transfer it, if it's not in those conditions, it starts to thaw. And the problem there is that there are a limited number of storage facilities, and to transfer it from that storage facility to a centre for distribution and delivery means that it's thawing as you're moving it. If we're then trying to move it to more than 1,000 care homes across Wales, we can't be clear that it will still be effective for use in each of those homes, and it's not something that you can transfer in very small quantities. So, the challenge then is how do we safely deliver this and get it to as many people, in accordance with the priorities that exist. And that's exactly what we're doing. It's also why I've been clear that the Oxford vaccine has lots of hope invested in it, because if that is approved for supply as well, that is something that you can deliver in a way that we're much more familiar with. So, when I have my flu vaccine, I go to a community pharmacy, I get a jab in the arm, and that's me done. There's not a complicated storage process; it's the same with general practice and others. The Oxford vaccine can be stored and moved in those circumstances, and so certainly that would make a much bigger difference, for not just care home residents, but other housebound groups of people, who will be right at the top of the vulnerability list. It's actually about protecting those people, which is why we've highlighted the practical challenge, and we'll continue to be honest and upfront with people about each of the choices we make.
Welsh: Na, nid wyf yn derbyn pwynt yr Aelod o gwbl; credaf ei bod yn hynod bwysig ein bod yn dilyn nid yn unig y cyngor proffesiynol ond y cyngor ar ddiogelwch ac effeithiolrwydd y brechlyn. Ac mae'n bwysig nodi, unwaith eto, ein bod yn siarad am yr un brechlyn hwn, brechlyn Pfizer sydd wedi'i gymeradwyo i gael ei gyflenwi heddiw, brechlyn y mae angen ei storio ar -70 gradd canradd. Wedyn, wrth ei dynnu allan, ac wrth i chi ei drosglwyddo, os na chaiff ei gadw o dan yr amodau hynny, mae'n dechrau dadmer. A'r broblem yno yw mai nifer cyfyngedig o gyfleusterau storio sy'n bodoli, ac mae ei drosglwyddo o'r cyfleuster storio i ganolfan ddosbarthu a chyflenwi'n golygu ei fod yn dadmer wrth i chi ei symud. Os ydym wedyn yn ceisio'i symud i fwy na 1,000 o gartrefi gofal ledled Cymru, ni allwn fod yn sicr y bydd yn dal i fod yn effeithiol i'w ddefnyddio ym mhob un o'r cartrefi hynny, ac nid yw'n rhywbeth y gallwch drosglwyddo cyfeintiau bach ohono. Felly, yr her wedyn yw sut y gallwn ei ddanfon yn ddiogel i gymaint o bobl â phosibl, yn unol â'r blaenoriaethau sy'n bodoli. A dyna'n union rydym yn ei wneud. Dyma hefyd pam rwyf wedi dweud yn glir fod cryn dipyn o obaith wedi'i fuddsoddi ym mrechlyn Rhydychen, oherwydd os caiff hwnnw ei gymeradwyo i gael ei gyflenwi hefyd, mae hwnnw'n rhywbeth y gallwch ei ddarparu mewn ffordd sy'n fwy cyfarwydd i ni. Felly pan fyddaf yn cael fy mrechlyn ffliw, rwy'n mynd i fferyllfa gymunedol, rwy'n cael pigiad yn fy mraich, a dyna ni. Nid oes proses storio gymhleth; mae'r un peth yn wir gyda meddygfeydd a mannau eraill. Gellir storio a symud brechlyn Rhydychen o dan yr amgylchiadau hynny, ac felly byddai hwnnw'n sicr yn gwneud gwahaniaeth mwy o lawer, nid yn unig i breswylwyr cartrefi gofal, ond i grwpiau eraill o bobl sy'n gaeth i'w cartrefi a fydd ar frig y rhestr o bobl agored i niwed. Mae'n ymwneud â diogelu'r bobl hynny, a dyna pam ein bod wedi tynnu sylw at yr her ymarferol, o byddwn yn parhau i fod yn onest ac yn agored gyda phobl ym mhob un o'r dewisiadau a wnawn.